- Transcenta Holding Limited, a global biotherapeutics company with integrated capabilities in discovery, completed a 105m USD crossover financing
- China Structural Reform Fund led the financing round, participated by new investors
- Existing investors including CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, Sequoia Capital China, and others also participated in this round
- The proceeds from new funding will used to accelerate ongoing clinical programs and prepare for commercialization
- Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development, and manufacturing
- In 2020, TST001, a CLDN18.2 targeting antibody and one of its leading programs, has been moving quickly in a clinic in both US and China
